{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T07:00:58Z","timestamp":1794294058805,"version":"4.9.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI16C2300"],"award-info":[{"award-number":["HI16C2300"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p><jats:italic>Mycoplasma pneumoniae<\/jats:italic>is a common pathogen that causes community-acquired pneumonia in school-age children. Macrolides are considered a first-line treatment for<jats:italic>M. pneumoniae<\/jats:italic>infection in children, but macrolide-refractory<jats:italic>M. pneumoniae<\/jats:italic>(MRMP) strains have become more common. In this study, we assessed the efficacy of tetracyclines and fluoroquinolones in MRMP treatment in children through a systematic review and meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two reviewers individually searched 10 electronic databases (Medline\/Pubmed, Embase, the Cochrane Library, and core Korean, Chinese, and Japanese journals) for papers published from January 1, 1990 to March 8, 2018. The following data for each treatment group were extracted from the selected studies: intervention (tetracyclines and fluoroquinolones\/comparator), patient characteristics (age and sex), and outcomes (fever duration, hospital stay length, treatment success rate, and defervescence rates 24, 48, and 72\u00a0h after starting treatment).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight studies involving 537 participants were included. Fever duration and hospital stay length were shorter in the tetracycline group than in the macrolide group (weighted mean difference [WMD]\u2009=\u2009\u2212\u00a01.45, 95% confidence interval [CI]: \u2212\u00a02.55 to \u2212\u00a00.36,<jats:italic>P<\/jats:italic>\u2009=\u20090.009; and WMD\u2009=\u2009\u2212\u00a03.33, 95% CI: \u2212\u00a04.32 to \u2212\u00a02.35,<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001, respectively). The therapeutic efficacy was significantly higher in the tetracycline group than in the macrolide group (odds ratio [OR]: 8.80, 95% CI: 3.12\u201324.82). With regard to defervescence rate, patients in the tetracycline group showed significant improvement compared to those in the macrolide group (defervescence rate after 24\u00a0h, OR: 5.34, 95% CI: 1.81\u201315.75; after 48\u00a0h, OR 18.37, 95% CI: 8.87\u201338.03; and after 72\u00a0h, OR: 40.77, 95% CI: 6.15\u2013270.12). There were no differences in fever improvement within 24\u00a0h in patients in the fluoroquinolone group compared to those in the macrolide group (OR: 1.11, 95% CI: 0.25\u20135.00), although the defervescence rate was higher after 48\u00a0h in the fluoroquinolone group (OR: 2.78, 95% CI: 1.41\u20135.51).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Tetracyclines may shorten fever duration and hospital stay length in patients with MRMP infection. Fluoroquinolones may achieve defervescence within 48\u00a0h in patients with MRMP infection. However, these results should be carefully interpreted as only a small number of studies were included, and they were heterogeneous.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-021-06508-7","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T18:02:33Z","timestamp":1632592953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Efficacy of tetracyclines and fluoroquinolones for the treatment of macrolide-refractory Mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Jong Gyun","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Kyung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Wook","family":"Eun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Sun","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hwa","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Jong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"issue":"3","key":"6508_CR1","first-page":"681","volume":"11","author":"RC Gordon","year":"2000","unstructured":"Gordon RC. Community-acquired pneumonia in adolescents. Adolesc Med. 2000;11(3):681\u201395.","journal-title":"Adolesc Med"},{"issue":"9","key":"6508_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1056\/NEJMoa1405870","volume":"372","author":"S Jain","year":"2015","unstructured":"Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, Stockmann C, Anderson EJ, Grijalva CG, Self WH, et al. Community-acquired pneumonia requiring hospitalization among US children. N Engl J Med. 2015;372(9):835\u201345.","journal-title":"N Engl J Med"},{"issue":"6","key":"6508_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1542\/peds.2013-3729","volume":"133","author":"E Biondi","year":"2014","unstructured":"Biondi E, McCulloh R, Alverson B, Klein A, Dixon A, Ralston S. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics. 2014;133(6):1081\u201390.","journal-title":"Pediatrics"},{"issue":"6","key":"6508_CR4","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1574-6976.2008.00129.x","volume":"32","author":"TP Atkinson","year":"2008","unstructured":"Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32(6):956\u201373.","journal-title":"FEMS Microbiol Rev"},{"issue":"12","key":"6508_CR5","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.rmed.2008.06.022","volume":"102","author":"A Defilippi","year":"2008","unstructured":"Defilippi A, Silvestri M, Tacchella A, Giacchino R, Melioli G, Di Marco E, Cirillo C, Di Pietro P, Rossi GA. Epidemiology and clinical features of Mycoplasma pneumoniae infection in children. Respir Med. 2008;102(12):1762\u20138.","journal-title":"Respir Med"},{"issue":"7","key":"6508_CR6","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1093\/cid\/cir531","volume":"53","author":"JS Bradley","year":"2011","unstructured":"Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL, Mace SE, McCracken GH Jr, Moore MR, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25-76.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"6508_CR7","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1128\/AAC.00663-13","volume":"57","author":"Y Kawai","year":"2013","unstructured":"Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, Saito A, Kondo E, Teranishi H, Wakabayashi T, et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother. 2013;57(8):4046\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"6508_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3345\/kjp.2017.60.5.151","volume":"60","author":"E Lee","year":"2017","unstructured":"Lee E, Cho HJ, Hong SJ, Lee J, Sung H, Yu J. Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children. Korean J Pediatr. 2017;60(5):151\u20137.","journal-title":"Korean J Pediatr"},{"issue":"4","key":"6508_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.diagmicrobio.2010.03.004","volume":"67","author":"Y Liu","year":"2010","unstructured":"Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, Wang M. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis. 2010;67(4):355\u20138.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"6508_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1128\/CMR.00114-16","volume":"30","author":"KB Waites","year":"2017","unstructured":"Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30(3):747\u2013809.","journal-title":"Clin Microbiol Rev"},{"issue":"20","key":"6508_CR11","doi-asserted-by":"publisher","first-page":"30247","DOI":"10.1016\/j.jmii.2020.10.002","volume":"S1684\u20131182","author":"TA Tsai","year":"2020","unstructured":"Tsai TA, Tsai CK, Kuo KC, Yu HR. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J Microbiol Immunol Infect. 2020;S1684\u20131182(20):30247\u201354. https:\/\/doi.org\/10.1016\/j.jmii.2020.10.002.","journal-title":"J Microbiol Immunol Infect"},{"issue":"3","key":"6508_CR12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1542\/peds.47.3.567","volume":"47","author":"ER Grossman","year":"1971","unstructured":"Grossman ER, Walchek A, Freedman H. Tetracyclines and permanent teeth: the relation between dose and tooth color. Pediatrics. 1971;47(3):567\u201370.","journal-title":"Pediatrics"},{"issue":"5","key":"6508_CR13","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1086\/516119","volume":"25","author":"JE Burkhardt","year":"1997","unstructured":"Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis. 1997;25(5):1196\u2013204.","journal-title":"Clin Infect Dis"},{"key":"6508_CR14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2706","author":"MA Jackson","year":"2016","unstructured":"Jackson MA, Schutze GE. Committee on infectious D: the use of systemic and topical fluoroquinolones. Pediatrics. 2016. https:\/\/doi.org\/10.1542\/peds.2016-2706.","journal-title":"Pediatrics"},{"key":"6508_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"key":"6508_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2008","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley-Blackwell; 2008."},{"issue":"4","key":"6508_CR17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","volume":"66","author":"SY Kim","year":"2013","unstructured":"Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, Jang BH, Son HJ. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66(4):408\u201314.","journal-title":"J Clin Epidemiol"},{"issue":"7414","key":"6508_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Research ed). 2003;327(7414):557\u201360.","journal-title":"BMJ (Clinical Research ed)"},{"issue":"12","key":"6508_CR19","first-page":"17","volume":"22","author":"X Han","year":"2016","unstructured":"Han X, Miao N, Wen H, Wang C. Minocycline in children with macrolide-resistant Mycoplasma pneumoniae pneumonia. J Pediatr Pharm. 2016;22(12):17\u20139.","journal-title":"J Pediatr Pharm"},{"issue":"08","key":"6508_CR20","first-page":"102","volume":"37","author":"J Li","year":"2017","unstructured":"Li J, Wang X, Wang M, Wang C, Song G. Analyze on the influence of minocycline combined with azithromycin on serum CRP, D-Dimer and lung function in the children with refractory mycoplasma pneumonia. Chinese J Biochem Pharm. 2017;37(08):102\u20135.","journal-title":"Chinese J Biochem Pharm."},{"issue":"05","key":"6508_CR21","first-page":"659","volume":"38","author":"Q Zhang","year":"2016","unstructured":"Zhang Q. Therapeutic effects of minocycline on MRMP in children over 8 years. Hebei Med J. 2016;38(05):659\u201361.","journal-title":"Hebei Med J"},{"issue":"12","key":"6508_CR22","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/cid\/cis784","volume":"55","author":"T Okada","year":"2012","unstructured":"Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, Chiba N, Iwata S, Ubukata K. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis. 2012;55(12):1642\u20139.","journal-title":"Clin Infect Dis"},{"issue":"21","key":"6508_CR23","first-page":"121","volume":"54","author":"H Ye","year":"2016","unstructured":"Ye H, Xu X, Li G, Zhu Y, Wei Y, Guan M. Evaluation of the curative effects of doxycycline in the treatment of pediatric macrolide-resistant mycoplasma pneumonia. China Modern Doctor. 2016;54(21):121\u20134.","journal-title":"China Modern Doctor"},{"issue":"2","key":"6508_CR24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1440-1843.2011.02102.x","volume":"17","author":"Y Kawai","year":"2012","unstructured":"Kawai Y, Miyashita N, Yamaguchi T, Saitoh A, Kondoh E, Fujimoto H, Teranishi H, Inoue M, Wakabayashi T, Akaike H, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology (Carlton, Vic). 2012;17(2):354\u201362.","journal-title":"Respirology (Carlton, Vic)"},{"issue":"5","key":"6508_CR25","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1128\/AAC.00048-13","volume":"57","author":"Y Kawai","year":"2013","unstructured":"Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, Saito A, Kondo E, Teranishi H, Ogita S, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother. 2013;57(5):2252\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"6508_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173635","volume":"12","author":"N Ishiguro","year":"2017","unstructured":"Ishiguro N, Koseki N, Kaiho M, Ariga T, Kikuta H, Togashi T, Oba K, Morita K, Nagano N, Nakanishi M, et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. PLoS ONE. 2017;12(3): e0173635.","journal-title":"PLoS ONE"},{"issue":"4","key":"6508_CR27","first-page":"351","volume":"103","author":"JM Conchie","year":"1970","unstructured":"Conchie JM, Munroe JD, Anderson DO. The incidence of staining of permanent teeth by the tetracyclines. Can Med Assoc J. 1970;103(4):351\u20136.","journal-title":"Can Med Assoc J"},{"issue":"5","key":"6508_CR28","doi-asserted-by":"publisher","first-page":"630","DOI":"10.14219\/jada.archive.1983.0111","volume":"106","author":"T Rebich Jr","year":"1983","unstructured":"Rebich T Jr, Kumar J, Brustman B. The St. Regis environmental health issue: assessment of dental defects. J Am Dent Assoc. 1983;106(5):630\u20133.","journal-title":"J Am Dent Assoc"},{"key":"6508_CR29","first-page":"692","volume":"6","author":"H Shwachman","year":"1958","unstructured":"Shwachman H, Fekete E, Kulczycki LL, Foley GE. The effect of long-term antibiotic therapy in patients with cystic fibrosis of the pancreas. Antibiot Annu. 1958;6:692\u20139.","journal-title":"Antibiot Annu"},{"issue":"223","key":"6508_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/adc.42.223.311","volume":"42","author":"JN Swallow","year":"1967","unstructured":"Swallow JN, De Haller J, Young WF. Side-effects to antibiotics in cystic fibrosis: dental changes in relation to antibiotic administration. Arch Dis Child. 1967;42(223):311\u20138.","journal-title":"Arch Dis Child"},{"issue":"7234","key":"6508_CR31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0140-6736(62)91840-8","volume":"1","author":"IS Wallman","year":"1962","unstructured":"Wallman IS, Hilton HB. Teeth pigmented by tetracycline. Lancet. 1962;1(7234):827\u20139.","journal-title":"Lancet"},{"issue":"5","key":"6508_CR32","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jpeds.2015.02.015","volume":"166","author":"SR Todd","year":"2015","unstructured":"Todd SR, Dahlgren FS, Traeger MS, Beltran-Aguilar ED, Marianos DW, Hamilton C, McQuiston JH, Regan JJ. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr. 2015;166(5):1246\u201351.","journal-title":"J Pediatr"},{"key":"6508_CR33","unstructured":"American A, of Pediatrics: Tetracyclines. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018: 905."},{"issue":"9","key":"6508_CR34","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/jcph.715","volume":"56","author":"K Patel","year":"2016","unstructured":"Patel K, Goldman JL. Safety concerns surrounding quinolone use in children. J Clin Pharmacol. 2016;56(9):1060\u201375.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"6508_CR35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/INF.0b013e3180cbd382","volume":"26","author":"GJ Noel","year":"2007","unstructured":"Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, Bagchi P, Balis DA, Blumer JL. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J. 2007;26(10):879\u201391.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"6508_CR36","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1542\/peds.2013-3636","volume":"134","author":"JS Bradley","year":"2014","unstructured":"Bradley JS, Kauffman RE, Balis DA, Duffy CM, Gerbino PG, Maldonado SD, Noel GJ. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014;134(1):e146-153.","journal-title":"Pediatrics"},{"key":"6508_CR37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3389\/fmicb.2016.00693","volume":"7","author":"T Yamazaki","year":"2016","unstructured":"Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front Microbiol. 2016;7:693.","journal-title":"Front Microbiol"},{"issue":"3","key":"6508_CR38","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1128\/AAC.49.3.1190-1193.2005","volume":"49","author":"D Gruson","year":"2005","unstructured":"Gruson D, Pereyre S, Renaudin H, Charron A, Bebear C, Bebear CM. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob Agents Chemother. 2005;49(3):1190\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"6508_CR39","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"LA Mandell","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al. Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-72.","journal-title":"Clin Infect Dis"},{"key":"6508_CR40","first-page":"1","volume":"6","author":"CA Hogan","year":"2016","unstructured":"Hogan CA, Puri L, Gore G, Pai M. Impact of fluoroquinolone treatment on delay of tuberculosis diagnosis: a systematic review and meta-analysis. J Clin Tuberc Other Mycobact Dis. 2016;6:1\u20137.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"1","key":"6508_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jmii.2014.11.003","volume":"49","author":"K-N Cheong","year":"2016","unstructured":"Cheong K-N, Chiu SS, Chan BW-K, To KK-W, Chan EL-Y, Ho P-L. Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failure. J Microbiol Immunol Infect. 2016;49(1):127\u201330.","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"6508_CR42","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1183\/09031936.00172510","volume":"37","author":"F Cardinale","year":"2011","unstructured":"Cardinale F, Chironna M, Dumke R, Binetti A, Daleno C, Sallustio A, Valzano A, Esposito S. Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia. Eur Respir J. 2011;37(6):1522\u20134.","journal-title":"Eur Respir J"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06508-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06508-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06508-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T04:52:50Z","timestamp":1673326370000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06508-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6508"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06508-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"21 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was needed because only data from previous published studies in which informed consent was obtained by primary investigators were retrieved and analyzed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1003"}}